
CITATION REPORT List of articles citing



DOI: 10.1097/00007691-199512000-00023 Therapeutic Drug Monitoring, 1995, 17, 681-4.

Source: https://exaly.com/paper-pdf/25635347/citation-report.pdf

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
240	Molecular mechanisms of action of new xenobiotic immunosuppressive drugs: tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and leflunomide. 1996 , 8, 710-20		170
239	Transplantation. 1996 , 8, 751-62		
238	Review of immunosuppression for lung transplantation. Novel drugs, new uses for conventional immunosuppressants, and alternative strategies. 1997 , 18, 353-66		28
237	Therapeutic monitoring of mycophenolic acid. A consensus panel report. 1998 , 31, 317-22		110
236	Mycophenolate mofetil strongly potentiates the anti-herpesvirus activity of acyclovir. 1998 , 40, 53-6		36
235	Mycophenolat Mofetil (CellCept[]) [Therapie-Monitoring nach Herztransplantation. 1998, 30, 37-39		3
234	High-performance liquid chromatography determination of mycophenolic acid and its glucuronide metabolite in human plasma. 1998 , 708, 229-34		41
233	How to handle mycophenolate mofetil in combination with tacrolimus?. 1998 , 30, 4094-5		10
232	Novel approaches in the treatment of lupus nephritis. 1998 , 7, 644-8		19
231	Developments in inhaled immunosuppressive therapy for the prevention of pulmonary graft rejection. 1998 , 9, 49-59		1
230	Clinical pharmacokinetics of mycophenolate mofetil. 1998 , 34, 429-55		638
229	Prospective investigations of concentration linical response for immunosuppressive drugs provide the scientific basis for therapeutic drug monitoring. 1998 , 44, 381-387		29
228	Simultaneous determination of mycophenolic acid and its glucuronide in human plasma using a simple high-performance liquid chromatography procedure. 1998 , 44, 1481-1488		110
227	The novel immunosuppressive agent mycophenolate mofetil markedly potentiates the antiherpesvirus activities of acyclovir, ganciclovir, and penciclovir in vitro and in vivo. 1998 , 42, 216-22		117
226	The antiherpesvirus activity of H2G [(R)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine] is markedly enhanced by the novel immunosuppressive agent mycophenolate mofetil. 1998 , 42, 3285-9		28
225	Hydroxyurea potentiates the antiherpesvirus activities of purine and pyrimidine nucleoside and nucleoside phosphonate analogs. 1999 , 43, 2885-92		10
224	Decrease of apoptosis rate in patients with renal transplantation treated with mycophenolate mofetil. 1999 , 82, 232-7		14

(2001-1999)

223	A simple HPLC method for monitoring mycophenolic acid and its glucuronidated metabolite in transplant recipients. 1999 , 37, 409-15	24
222	The therapeutic prescription for the organ transplant recipient: the linkage of immunosuppression and antimicrobial strategies. 1999 , 1, 29-39	40
221	The kinetics of mycophenolic acid and its glucuronide metabolite in adult kidney transplant recipients. 1999 , 66, 492-500	106
220	Interleukin-2 inhibitors in autoimmune disease. 1999 , 9, 27-39	7
219	The replacement of azathioprine by mycophenolate mofetil in pediatric patients with specific risks in renal transplantation. 1999 , 31, 2279	4
218	One and a half years of experience with mycophenolate mofetil (Cellcept) in cardiac transplantation: a prospective, randomized study. 1999 , 31, 3291-3	7
217	The effect of renal insufficiency on mycophenolic acid protein binding. 1999 , 39, 715-20	125
216	Evaluation of limited sampling strategies for estimation of 12-hour mycophenolic acid area under the plasma concentration-time curve in adult renal transplant patients. <i>Therapeutic Drug Monitoring</i> 3.2, 2000 , 22, 549-54	53
215	Pharmacodynamics of mycophenolic acid in heart allograft recipients: correlation of lymphocyte proliferation and activation with pharmacokinetics and graft histology. <i>Transplantation</i> , 2000 , 70, 1038-49 ⁸	38
214	Therapeutic drug monitoring in solid-organ transplant recipients. <i>Current Opinion in Organ Transplantation</i> , 2000 , 5, 330-335	3
213	Immunologic considerations in composite tissue transplantation: overview. 2000, 20, 412-9	27
212	Quantification of free mycophenolic acid by high-performance liquid chromatography-atmospheric pressure chemical ionisation tandem mass spectrometry. 2000 , 748, 151-6	29
211	Assessment of Mycophenolic Acid-induced Immunosuppression: A New Approach. 2000, 46, 1376-1383	40
210	A Specific Artificial Antibody toward Mycophenolic Acid Prepared by Molecular Imprinting. 2000 , 46, 1516-1518	11
209	Advances in therapeutic drug monitoring for immunosuppressants: a review of sirolimus. Introduction and overview. 2000 , 22 Suppl B, B1-13	15
208	Conformational constraints in NAD analogs: implications for dehydrogenase binding and specificity. 2000 , 40, 405-26	4
207	The potential of newer immunomodulating drugs in the treatment of uveitis: a review. 2000 , 13, 397-408	10
206	Mycophenolate mofetil treatment accelerates recovery from experimental allergic encephalomyelitis. 2001 , 1, 1709-23	24

205	Determination of the effects of mycophenolic acid on the nucleotide pool of human peripheral blood mononuclear cells in vitro by high-performance liquid chromatography. 2001 , 310, 81-7		19	
204	Novel approaches in the treatment of lupus nephritis. 2001 , 10, 1117-30		6	
203	La transplantation de myoblastes normaux ou gfiliquement modifili pour le traitement de maladies httlitaires ou acquises. 2001 , 195, 29-37		4	
202	Combined immunosuppression of mycophenolate mofetil and FK506 for myoblast transplantation in mdx mice. <i>Transplantation</i> , 2001 , 72, 38-44	1.8	24	
201	In vivo higher glucuronidation of mycophenolic acid in male than in female recipients of a cadaveric kidney allograft and under immunosuppressive therapy with mycophenolate mofetil. <i>Therapeutic Drug Monitoring</i> , 2001 , 23, 520-5	3.2	37	
200	Determination of mycophenolic acid and its phenol glucuronide metabolite in human plasma and urine by high-performance liquid chromatography. 2001 , 763, 35-45		35	
199	Inosine monophosphate dehydrogenase (IMPDH) inhibition in vitro suppresses lymphocyte proliferation and the production of immunoglobulins, autoantibodies and cytokines in splenocytes from MRLlpr/lpr mice. 2001 , 124, 486-91		17	
198	Pediatric kidney transplantation: historic hallmarks and a personal perspective. 2001 , 5, 239-45		12	
197	VX-497: a novel, selective IMPDH inhibitor and immunosuppressive agent. 2001 , 90, 625-37		53	
196	Possible implication of thiopurine S-methyltransferase in occurrence of infectious episodes during maintenance therapy for childhood lymphoblastic leukemia with mercaptopurine. 2001 , 15, 1706-12		32	
195	Antiviral activity and mode of action studies of ribavirin and mycophenolic acid against orthopoxviruses in vitro. 2001 , 12, 327-35		63	
194	Sanglifehrin A, a novel cyclophilin-binding compound showing immunosuppressive activity with a new mechanism of action. 2001 , 166, 7165-71		87	
193	Novel therapies in vasculitis. 2001 , 10, 1279-89		31	
192	Influence of mycophenolic acid on inosine 5Rmonophosphate dehydrogenase activity in human peripheral blood mononuclear cells. 2002 , 318, 71-7		19	
191	Mycophenolate mofetil in combination with recombinant interferon alfa-2a in interferon-nonresponder patients with chronic hepatitis C. 2002 , 37, 843-7		25	
190	Novel assays of multiple lymphocyte functions in whole blood measure: new mechanisms of action of mycophenolate mofetil in vivo. 2002 , 10, 1-14		38	
189	How pharmacokinetic and pharmacodynamic drug monitoring can improve outcome in solid organ transplant recipients. 2002 , 9, 211-4		21	
188	Neue TherapieansEze bei chronisch entzEdlichen Darmerkrankungen. 2002 , 18, 341-348			

(2005-2002)

187	Induction of apoptosis and modulation of activation and effector function in T cells by immunosuppressive drugs. 2002 , 128, 255-66		118
186	Rapid determination of mycophenolic acid in plasma by reversed-phase high-performance liquid chromatography. 2002 , 776, 251-4		19
185	Mycophenolic acid reduces renin-angiotensin-system activity in cultured mouse medullary thick ascending limb cells. <i>Transplant International</i> , 2002 , 15, 655-659	3	1
184	Mycophenolate mofetil (CellCept) for psoriasis: a two-center, prospective, open-label clinical trial. 2003 , 7, 193-7		23
183	High-performance liquid chromatographic method for mycophenolic acid and its glucuronide in serum and urine. 2003 , 28, 17-22		17
182	Population pharmacokinetic analysis of mycophenolic acid in renal transplant recipients following oral administration of mycophenolate mofetil. 2003 , 56, 188-97		51
181	Can xipamide or tacrolimus inhibit the glucuronidation of mycophenolic acid in rat liver slices?. 2003 , 54, 375-9		7
180	Mycophenolic acid-induced apoptotic signal transduction in MOLT-4 T-cell. 2003, 35, 564-6		
179	Immunosuppression with mycophenolic acid: one size does not fit all. <i>Journal of the American Society of Nephrology: JASN</i> , 2003 , 14, 2414-6	12.7	31
178	Mycophenolate Mofetil (CellCept[]) for Psoriasis: A Two-Center, Prospective, Open-Label Clinical Trial. 2003 , 7, 193-197		38
177	Review of the immunosuppressant enteric-coated mycophenolate sodium. 2004, 5, 1333-45		71
176	Augmentation of T-cell apoptosis by immunosuppressive agents. 2004 , 18 Suppl 12, 72-5		23
175	Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. 2004 , 4, 231-6		246
174	Monitoring immunosuppressive drugs. 2004 , 273-296		1
173	Characterization of a phase 1 metabolite of mycophenolic acid produced by CYP3A4/5. <i>Therapeutic Drug Monitoring</i> , 2004 , 26, 600-8	3.2	58
172	Comparison of liquid chromatography-tandem mass spectrometry with a commercial enzyme-multiplied immunoassay for the determination of plasma MPA in renal transplant recipients and consequences for therapeutic drug monitoring. <i>Therapeutic Drug Monitoring</i> , 2004 ,	3.2	73
171	Mycophenolate mofetil is compatible with CD28/CD154 costimulatory blockade in preventing transplant rejection. <i>Transplantation</i> , 2005 , 79, 736	1.8	2
170	[Relationship between dose of mycophenolate mofetil and the occurrence of cytomegalovirus infection and diarrhea in renal transplant recipients]. 2005 , 125, 177-85		5

169	Simple High-Performance Liquid Chromatographic Assay, with Post-Column Derivatization, for Simultaneous Determination of Mycophenolic Acid and its Glucuronide Metabolite in Human Plasma and Urine. 2005 , 62, 363-371	8	3
168	Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil. 2005 , 19, 199-206	1	107
167	Current Immunosuppressive Drugs in Renal Transplantation. 2005 , 2, 187-193		
166	Therapie gastroenterologischer Krankheiten. 2005,	2	<u>2</u>
165	Intraindividual and interindividual variations in the pharmacokinetics of mycophenolic acid in liver transplant patients. 2005 , 45, 34-41	ϵ	65
164	The use of systemic immune moderators in dermatology: an update. 2005 , 23, 259-300	4	13
163	Newer immunosuppressive drugs in organ transplantation: improving outcomes 2005, 1, 19-24		
162	Mycophenolate mofetil in organ transplantation: focus on metabolism, safety and tolerability. 2005 , 1, 505-26	7	70
161	Pharmacokinetics and pharmacodynamics of low dose mycophenolate mofetil in HIV-infected patients treated with abacavir, efavirenz and nelfinavir. 2005 , 44, 525-38	1	13
160	Enteric-coated mycophenolate sodium: tolerability profile compared with mycophenolate mofetil. 2005 , 65, 1037-50	ϵ	50
159	Traditional and newer therapeutic options for psoriatic arthritis: an evidence-based review. 2005 , 65, 1223-38	1	13
158	Enteric-coated mycophenolate sodium: role in transplantation. <i>Therapy: Open Access in Clinical Medicine</i> , 2006 , 3, 201-214	1	
157	Activation of the purine salvage pathway in mononuclear cells of cardiac recipients treated with mycophenolate mofetil. <i>Transplantation</i> , 2006 , 82, 113-8	1	14
156	A placebo-controlled pilot study of intensification of antiretroviral therapy with mycophenolate mofetil. 2006 , 3, 16	5	5
155	Investigation on pharmacokinetics of mycophenolic acid in Chinese adult renal transplant patients. 2006 , 62, 446-52	2	29
154	Mycophenolic acid trough level monitoring in solid organ transplant recipients treated with mycophenolate mofetil: association with clinical outcome. 2006 , 22, 2355-64	3	34
153	Therapeutic drug monitoring of mycophenolic acid. 2007 , 2, 1062-72	ϵ	50
152	Gender-related differences in mycophenolate mofetil-induced gastrointestinal toxicity in rats. 2007 , 35, 449-54	1	[4

151	Antibiotic treatment strategies for Helicobacter pylori infection. 2007 , 2, 11-7		18
150	Validation of immunological biomarkers for the pharmacodynamic monitoring of immunosuppressive drugs in humans. <i>Therapeutic Drug Monitoring</i> , 2007 , 29, 77-86	3.2	56
149	Limited sampling strategy for the estimation of mycophenolic acid area under the plasma concentration-time curve in adult patients undergoing liver transplant. <i>Therapeutic Drug Monitoring</i> , 2007 , 29, 207-14	3.2	11
148	Novel therapies for cytomegalovirus disease. 2007 , 2, 53-72		34
147	Sensitive high-performance liquid chromatography-tandem mass spectrometry method for quantitative analysis of mycophenolic acid and its glucuronide metabolites in human plasma and urine. 2007 , 858, 159-67		27
146	Pharmacokinetic and pharmacodynamic comparison of enteric-coated mycophenolate sodium and mycophenolate mofetil in maintenance renal transplant patients. 2007 , 7, 888-98		91
145	Verbesserung der Arzneimittelsicherheit durch Therapiemonitoring. 2007, 155, 724-732		4
144	Association of four DNA polymorphisms with acute rejection after kidney transplantation. <i>Transplant International</i> , 2008 , 21, 879-91	3	87
143	Lymphocyte activation and correlation with IMPDH activity under therapy with mycophenolate mofetil. 2008 , 394, 67-71		12
142	Measurement of mycophenolic acid in plasma or serum by a commercial enzyme inhibition technique in comparison with a high performance liquid chromatography method. 2008 , 46, 1281-4		2
141	In vitro end points for the assessment of cellular immune response-modulating drugs. 2009 , 4, 473-93		2
140	Effect of mycophenolate acyl-glucuronide on human recombinant type 2 inosine monophosphate dehydrogenase. 2009 , 55, 986-93		27
139	Diagnosis and therapy of autoimmune hepatitis. 2009 , 9, 847-60		22
138	The role of adjuvant agents in treating fungal diseases. 2009 , 3, 117-126		
137	Prospective monitoring of Epstein-Barr virus DNA in adult renal transplant recipients during the early posttransplant period: role of mycophenolate mofetil. <i>Transplantation</i> , 2009 , 87, 852-6	1.8	22
136	What is the value of mycophenolate mofetil as induction and maintenance therapy in lupus nephritis?. 2009 , 21, 256-61		10
135	Performance of the new mycophenolate assay based on IMPDH enzymatic activity for pharmacokinetic investigations and setup of Bayesian estimators in different populations of allograft recipients. <i>Therapeutic Drug Monitoring</i> , 2009 , 31, 443-50	3.2	11
134	Pharmacokinetics of mycophenolic acid and its glucuronidated metabolites in stable islet transplant recipients. <i>Therapeutic Drug Monitoring</i> , 2010 , 32, 373-8	3.2	3

133	Polymorphisms in type I and II inosine monophosphate dehydrogenase genes and association with clinical outcome in patients on mycophenolate mofetil. 2010 , 20, 537-43		42
132	Population pharmacokinetics analysis of mycophenolic acid in adult kidney transplant patients with chronic graft dysfunction. <i>Therapeutic Drug Monitoring</i> , 2010 , 32, 427-32	3.2	13
131	Mycophenolate in the remission induction of a patient with acquired haemophilia A. 2010, 16, 180-2		3
130	Progressive multifocal leukoencephalopathy and newer biological agents. 2010 , 33, 969-83		88
129	Enteric-coated mycophenolate sodium versus cyclosporin A as long-term treatment in adult patients with severe atopic dermatitis: a randomized controlled trial. 2011 , 64, 1074-84		130
128	Beta Cell Replacement Therapy. 2011 ,		1
127	Estudio de biodisponibilidad relativa entre dos formulaciones orales de micofenolato mofetilo en voluntarios sanos. 2011 , 139, 902-908		О
126	Antirejection drugs and immunosuppressants. 830-841		1
125	Idiopathic transverse myelitis and neuromyelitis optica: clinical profiles, pathophysiology and therapeutic choices. 2011 , 9, 417-28		36
124	Roles of the immune system in skin cancer. 2011 , 165, 953-65		114
124	Roles of the immune system in skin cancer. 2011 , 165, 953-65 Pharmacokinetics and pharmacodynamics of mycophenolic acid and their relation to response to therapy of childhood-onset systemic lupus erythematosus. 2011 , 40, 307-13		114 45
	Pharmacokinetics and pharmacodynamics of mycophenolic acid and their relation to response to		, i
123	Pharmacokinetics and pharmacodynamics of mycophenolic acid and their relation to response to therapy of childhood-onset systemic lupus erythematosus. 2011 , 40, 307-13		45
123	Pharmacokinetics and pharmacodynamics of mycophenolic acid and their relation to response to therapy of childhood-onset systemic lupus erythematosus. 2011 , 40, 307-13 Potential teratogenic effects of allopurinol: a case report. 2011 , 155A, 2247-52 Female spontaneously hypertensive rats have greater renal anti-inflammatory T lymphocyte		45
123 122 121	Pharmacokinetics and pharmacodynamics of mycophenolic acid and their relation to response to therapy of childhood-onset systemic lupus erythematosus. 2011 , 40, 307-13 Potential teratogenic effects of allopurinol: a case report. 2011 , 155A, 2247-52 Female spontaneously hypertensive rats have greater renal anti-inflammatory T lymphocyte infiltration than males. 2012 , 303, R359-67 Treatment-related progressive multifocal leukoencephalopathy: current understanding and future		45 19 59
123 122 121 120	Pharmacokinetics and pharmacodynamics of mycophenolic acid and their relation to response to therapy of childhood-onset systemic lupus erythematosus. 2011 , 40, 307-13 Potential teratogenic effects of allopurinol: a case report. 2011 , 155A, 2247-52 Female spontaneously hypertensive rats have greater renal anti-inflammatory T lymphocyte infiltration than males. 2012 , 303, R359-67 Treatment-related progressive multifocal leukoencephalopathy: current understanding and future steps. 2012 , 3, 227-39	6	45 19 59 52
123 122 121 120	Pharmacokinetics and pharmacodynamics of mycophenolic acid and their relation to response to therapy of childhood-onset systemic lupus erythematosus. 2011, 40, 307-13 Potential teratogenic effects of allopurinol: a case report. 2011, 155A, 2247-52 Female spontaneously hypertensive rats have greater renal anti-inflammatory T lymphocyte infiltration than males. 2012, 303, R359-67 Treatment-related progressive multifocal leukoencephalopathy: current understanding and future steps. 2012, 3, 227-39 The treatment of autoimmune hepatitis. 2012, 7, 318-27 Molecular biology, epidemiology, and pathogenesis of progressive multifocal	6	45 19 59 52 5

(2014-2012)

115	Analytical validation of a homogeneous immunoassay for determination of mycophenolic acid in human plasma. 2012 , 44, 2669-72	8
114	Enteric-coated mycophenolate sodium immunosuppression in renal transplant patients: efficacy and dosing. 2012 , 26, 233-40	14
113	A purine nucleotide biosynthesis enzyme guanosine monophosphate reductase is a suppressor of melanoma invasion. 2013 , 5, 493-507	29
112	Evidence for rapamycin toxicity in pancreatic Eells and a review of the underlying molecular mechanisms. 2013 , 62, 2674-82	133
111	Mycophenolate fetal toxicity and risk evaluation and mitigation strategies. 2013, 13, 1383-9	57
110	Case report: Crohnß-like mycophenolate-induced colitis, a fallout in steroid-free regimens. 2013 , 45, 842-4	10
109	Nuclear translocation of nuclear factor of activated T cells (NFAT) as a quantitative pharmacodynamic parameter for tacrolimus. 2013 , 83, 1096-104	38
108	WITHDRAWN: Use of mycophenolic acid in lupus nephritis. 2013,	
107	Mycophenolic acid derivative 118 improves outcome of skin grafts by suppressing IL-17 production. 2013 , 34, 921-9	
106	Peripheral CD24hi CD27+ CD19+ B cells subset as a potential biomarker in naWe systemic lupus erythematosus. 2013 , 16, 698-708	15
105	Molecular signatures in skin associated with clinical improvement during mycophenolate treatment in systemic sclerosis. 2013 , 133, 1979-89	102
104	Outcomes of pregnancies fathered by solid-organ transplant recipients exposed to mycophenolic acid products. 2013 , 23, 153-7	59
103	Tacrolimus inhibits NF- B activation in peripheral human T cells. 2013 , 8, e60784	35
102	Measuring T-cell responses against LCV and CMV in cynomolgus macaques using ELISPOT: potential application to non-clinical testing of immunomodulatory therapeutics. 2014 , 11, 35-43	8
101	Randomized trial of enteric-coated mycophenolate sodium versus mycophenolate mofetil in multi-system autoimmune disease. 2014 , 7, 562-8	4
100	Mycophenolate mofetil improves neurological function and alters blood T-lymphocyte subsets in rats with experimental autoimmune encephalomyelitis. 2014 , 42, 530-41	3
99	Unusually late-onset mycophenolate mofetil-related colitis. 2014 , 71, 1858-61	7
98	Conformational changes involving ammonia tunnel formation and allosteric control in GMP synthetase. 2014 , 545, 22-32	8

97	Determination of mycophenolic acid in human plasma by ultra performance liquid chromatography tandem mass spectrometry. 2014 , 4, 205-216	12
96	Mechanisms of Immunosuppressive Drugs. 2014 , 127-141	2
95	Unmet needs in the treatment of autoimmunity: from aspirin to stem cells. 2014, 13, 331-46	17
94	Immunosuppressants and alloimmunization against red blood cell transfusions. 2014 , 54, 1981-7	44
93	Mycophenolate mofetil in the treatment of SLE and systemic vasculitis: experience at a single university center. 2014 , 23, 299-304	8
92	Safety considerations when prescribing immunosuppression medication to pregnant women. 2014 , 13, 1591-9	23
91	Liquid chromatography tandem mass spectrometry method for the quantitation of mycophenolate mofetil in human plasma: Application to a bioequivalence study and metabolite identification. 2015 , 38, 3533-44	2
90	Lung transplantation: perioperative pharmacology and anesthetic considerations. 2015, 10, 22-34	1
89	Pneumonia in Solid-Organ Transplant Recipients. 2015 , 1, 293-331	32
88	Synergistic Inhibition of Tumor Necrosis Factor-Alpha-Stimulated Pro-Inflammatory Cytokine Expression in HaCaT Cells by a Combination of Rapamycin and Mycophenolic Acid. 2015 , 27, 32-9	11
87	Effects of topically applied rapamycin and mycophenolic acid on TNCB-induced atopic dermatitis-like skin lesions in NC/Nga mice. 2015 , 26, 432-8	18
86	Use of mycophenolate in ANCA-associated renal vasculitis: 13 years of experience at a university hospital. 2015 , 30 Suppl 1, i132-7	8
85	Pharmacological targeting of guanosine monophosphate synthase suppresses melanoma cell invasion and tumorigenicity. 2015 , 22, 1858-64	17
84	Micro and nanoparticle drug delivery systems for preventing allotransplant rejection. 2015, 160, 24-35	39
83	Gastrointestinal toxicity of mycophenolate mofetil in rats: Effect of administration time. 2015, 32, 1373-84	3
82	A risk classification for immunosuppressive treatment-associated progressive multifocal leukoencephalopathy. 2015 , 21, 623-31	30
81	Treatment of New-Onset Psoriasis Post-Kidney Transplant. 2016 , 1, 96-101	
80	Active and Repressive Chromatin-Associated Proteome after MPA Treatment and the Role of Midkine in Epithelial Monolayer Permeability. 2016 , 17,	3

79	Immune Mechanisms in Myelodysplastic Syndrome. 2016 , 17,	35
78	Simultaneous quantification of mycophenolic acid and its glucuronide metabolites in human plasma by an UPLC-MS/MS assay. 2016 , 30, 1648-55	6
77	Immunopharmacological Drugs. 2016 , 549-572	O
76	Critical review of the current recommendations for the treatment of systemic inflammatory rheumatic diseases during pregnancy and lactation. 2016 , 15, 955-63	58
75	An additional Meyerozyma guilliermondii IMH3 gene confers mycophenolic acid resistance in fungal CTG clade species. 2016 , 16,	3
74	Management of Pemphigus Vulgaris. 2016 , 33, 910-58	45
73	Usefulness of mycophenolic acid monitoring with PETINIA for prediction of adverse events in kidney transplant recipients. 2016 , 76, 296-303	5
72	Current methods of the analysis of immunosuppressive agents in clinical materials: A review. 2016 , 127, 207-31	52
71	High expression of CD38, CD69, CD95 and CD154 biomarkers in cultured peripheral T lymphocytes correlates with an increased risk of acute rejection in liver allograft recipients. 2016 , 221, 595-603	6
70	The compelling case for therapeutic drug monitoring of mycophenolate mofetil therapy. 2017 , 32, 21-29	25
69	Efficacy of mycophenolate treatment in adults with steroid-dependent/frequently relapsing idiopathic nephrotic syndrome. 2017 , 10, 632-638	2
68	Combination Immunotherapy for Type 1 Diabetes. 2017 , 17, 50	12
67	Development of a Liquid Chromatography-Tandem Mass Spectrometric Method for Quantification of Mycophenolic Acid and Its Glucuronides in Dried Blood Spot Samples. <i>Therapeutic Drug Monitoring</i> , 2017 , 39, 648-653	6
66	Mycophenolate Sodium for Children with Frequently Relapsing or Steroid Dependent Nephrotic Syndrome. 2017 , 54, 885-886	1
65	Nanotechnological Approaches to Immunosuppression and Tolerance Induction. 2017 , 4, 159-168	7
64	Clinical Pharmacokinetics of Mycophenolic Acid in Hematopoietic Stem Cell Transplantation Recipients. 2017 , 42, 183-189	16
63	Topical mycophenolate mofetil in the treatment of vitiligo: a pilot study. 2017, 7, 31-33	7
62	Immunosuppressive Drugs. 2017 , 983-998.e4	2

61	Myeloid Neoplasms Following Solid Organ Transplantation: Clinicopathologic Studies of 23 Cases. 2017 , 149, 55-66	8
60	Limited Sampling Strategy for the Estimation of Mycophenolic Acid and its Acyl Glucuronide Metabolite Area under the Concentration-Time Curve in Japanese Lung Transplant Recipients. 2019 , 22, 407-417	2
59	European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period. 2019 , 33, 1644-1659	42
58	A novel role for myeloid endothelin-B receptors in hypertension. 2019 , 40, 768-784	18
57	Use of synthetic and biologic DMARDs during pregnancy. 2019 , 15, 27-39	6
56	Safety of systemic treatments for Behetß syndrome. 2020 , 19, 1269-1301	3
55	Immunosuppressive and Immunomodulating Therapy for Atopic Dermatitis in Pregnancy: An Appraisal of the Literature. 2020 , 10, 1215-1228	7
54	Mycophenolate mofetil, azathioprine and tacrolimus: mechanisms in rheumatology. 2020 , 16, 167-178	51
53	Cytotoxic drug treatment. 2021 , 611-620	
52	Nanoparticulate Mycophenolic Acid Eye Drops - Analytical Validation of a High Performance Liquid Chromatography Assay and Stability Studies. 2021 , 9, 101-110	
51	De Novo Carcinoma after Solid Organ Transplantation to Give Insight into Carcinogenesis in General-A Systematic Review and Meta-Analysis. 2021 , 13,	1
50	A Drug Screening Pipeline Using 2D and 3D Patient-Derived In Vitro Models for Pre-Clinical Analysis of Therapy Response in Glioblastoma. 2021 , 22,	9
49	A yeast-optimized single-cell transcriptomics platform elucidates how mycophenolic acid and guanine alter global mRNA levels. 2021 , 4, 822	2
48	Approaches for Controlling Antibody-Mediated Allograft Rejection Through Targeting B Cells. 2021 , 12, 682334	1
47	Influence of immunomodulatory drugs on the gut microbiota. 2021 , 233, 144-161	4
46	Use of immunosuppression in non-transplant hepatology. 2021 , 54-55, 101760	O
45	Mycophenolate Mofetil and Plasmapheresis: A Treatment Option for Severe Insulin Resistance caused by Insulin Antibodies. 2021 , 7, 307-309	1
44	Mycophenolate-Induced Colitis: A Rare Side Effect. 2021 , 13, e18250	

43	Pharmacokinetics of mycophenolate mofetil in heart transplant recipients. 1998 , 431, 801-3		7
42	Immunosuppressive Drugs. 2013 , 941-956.e4		2
41	Population pharmacokinetics of mycophenolic acid in adult kidney transplant patients under prednisone and tacrolimus regimen. 2020 , 150, 105370		7
40	Internally ratiometric fluorescent sensors for evaluation of intracellular GTP levels and distribution. <i>Nature Methods</i> , 2017 , 14, 1003-1009	21.6	32
39	Effect of mycophenolic acid glucuronide on inosine monophosphate dehydrogenase activity. <i>Therapeutic Drug Monitoring</i> , 1997 , 19, 358-60	3.2	46
38	The immunosuppressive agent mycophenolate mofetil markedly potentiates the activity of lobucavir [1R(1alpha,2beta,3alpha)]-9-[2,3-bis(hydroxymethyl)cyclobutyl]guanine against different herpes viruses. <i>Transplantation</i> , 1999 , 67, 760-4	1.8	16
37	Cyclosporine, FK506, mycophenolate mofetil, and prednisolone differentially modulate cytokine gene expression in human airway-derived epithelial cells. <i>Transplantation</i> , 2000 , 69, 1408-13	1.8	25
36	Analogs of 1,25-dihydroxyvitamin D3 as dose-reducing agents for classical immunosuppressants. <i>Transplantation</i> , 2000 , 69, 1932-42	1.8	93
35	The impact of routine mycophenolate mofetil drug monitoring on the treatment of cardiac allograft rejection. <i>Transplantation</i> , 2000 , 69, 2326-30	1.8	68
34	Bronchiolitis obliterans syndrome. <i>Current Opinion in Organ Transplantation</i> , 1999 , 4, 254-263	2.5	7
33	Mycophenolate mofetil-induced liver injury in a patient with aquaporin-4 antibody positive transverse myelitis. <i>BMJ Case Reports</i> , 2020 , 13,	0.9	1
32	Congenital Esophageal Atresia and Microtia in a Newborn Secondary to Mycophenolate Mofetil Exposure During Pregnancy: A Case Report and Review of the Literature. <i>American Journal of Case Reports</i> , 2018 , 19, 523-526	1.3	4
31	Pharmacokinetics of mycophenolic acid in Chinese kidney transplant patients. <i>Journal of Zhejiang University Science B</i> , 2005 , 6, 885-91		16
30	Newer immunosuppressive drugs: a review. <i>Journal of the American Society of Nephrology: JASN</i> , 1999 , 10, 1366-80	12.7	184
29	Correlation of abnormal histology with endoscopic findings among mycophenolate mofetil treated patients. <i>World Journal of Gastrointestinal Endoscopy</i> , 2017 , 9, 405-410	2.2	1
28	Future developments in treatment of atopic dermatitis. 2000 , 173-197		
27	New Immunosuppressive Agents. 2001 , 233-266		
26	Mycophenolate Mofetil and Azathioprine. 2001 , 85-110		

1

Immunoregulatory Drugs. 2009, 909-927

CITATION REPORT

7	Chemotherapy. 2022 , 10, 1631	1
6	Sarcoidosis: Updates on therapeutic drug trials and novel treatment approaches. 9,	O
5	Proteomic study on the lymphocytes from pregnant Wistar rat females treated with immunosuppressive regimen.	О
4	Immunosuppression and Solid Organ Transplantation. 2022 , 3-35	O
3	Polyketides from Fungi. 2023 , 555-605	O
2	Nucleotide metabolism: a pan-cancer metabolic dependency.	O
1	Development and application of a thin-film molecularly imprinted polymer for the measurement of mycophenolic acid in human plasma.	О